[Involvement of matrix metalloproteinases (MMPs) in cutaneous melanoma progression].
Among skin cancers, melanoma is probably the most highly invasive and metastasizing, with a poor outcome. During melanoma progression, tumor cells must across the dermal-epidermal junction, and invade the dermis, its principal site of propagation. Therefore, degradation of matrix proteins constituting dermal-epidermal junction and dermis by proteolytic enzymes is an essential step of melanoma invasion. Serines proteinases and Matrix Metalloproteinases (MMPs) families are the main degrading substances involved in this process. Among MMPs, the expression of MMP-1, -2, -3, -9, -14, 15, -16 by melanoma cells was shown in vitro and in vivo, and correlated with the invasive phenotype. In addition to disrupt matrix proteins, MMPs can also cleave non matrix components such as cytokines, and growth factors. The modifications generated by the remodeling of matrix and non-matrix components can influence melanoma cells proliferation, adhesion, vascularization, survival, proteases expression, and migration. Thus, using inhibitors in order to control expression, activation and activity of MMPs could regulate cellular process which led to melanoma progression.
Ntayi
C
C
Laboratoire de recherche en dermatologie, Faculté de médecine, Université de Reims-Champagne-Ardenne, 51, rue Cognacq-Jay, 51095 Reims, France. carole.ntayi@caramail.com
Hornebeck
W
W
Bernard
P
P
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D016207:Cytokines / Q000378:metabolism; D018450:Disease Progression; D004789:Enzyme Activation; D016326:Extracellular Matrix Proteins / Q000378:metabolism; D006133:Growth Substances / Q000378:metabolism; D006801:Humans; D020778:Matrix Metalloproteinase 2 / Q000172:deficiency / Q000235:genetics; D020782:Matrix Metalloproteinases / Q000502:physiology*; D008545:Melanoma / Q000188:drug therapy / Q000201:enzymology* / Q000473:pathology; D008546:Melanoma, Experimental / Q000188:drug therapy / Q000201:enzymology / Q000473:pathology; D051379:Mice; D018345:Mice, Knockout; D009363:Neoplasm Proteins / Q000502:physiology*; D011480:Protease Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D012697:Serine Endopeptidases / Q000502:physiology; D012878:Skin Neoplasms / Q000188:drug therapy / Q000201:enzymology / Q000473:pathology; D023041:Xenograft Model Antitumor Assays
D000970:Antineoplastic Agents; D016207:Cytokines; D016326:Extracellular Matrix Proteins; D006133:Growth Substances; D009363:Neoplasm Proteins; D011480:Protease Inhibitors; D012697:Serine Endopeptidases; D020782:Matrix Metalloproteinases; D020778:Matrix Metalloproteinase 2